Mustang Bio Inc
MBIO
Company Profile
Business description
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Contact
95 Sawyer Road
Suite 110
WalthamMA02453
USAT: +1 781 652-4500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
Alphabet raises $80 billion for AI efforts
$10 billion private placement to Berkshire Hathaway as part of equity raise.
stocks
SpaceX: What investors need to know about its enormous upcoming IPO
Morningstar launches research coverage of SpaceX.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,026.50 | 6.20 | 0.07% |
| CAC 40 | 8,209.09 | 62.50 | 0.77% |
| DAX 40 | 25,124.17 | 121.13 | 0.48% |
| Dow JONES (US) | 51,307.79 | 228.91 | 0.45% |
| FTSE 100 | 10,373.51 | 34.56 | 0.33% |
| HKSE | 25,587.30 | 451.02 | -1.73% |
| NASDAQ | 27,093.90 | 7.09 | 0.03% |
| Nikkei 225 | 68,710.50 | 1,976.26 | 2.96% |
| NZX 50 Index | 13,133.67 | 37.04 | -0.28% |
| S&P 500 | 7,609.78 | 9.82 | 0.13% |
| S&P/ASX 200 | 8,794.90 | 15.10 | 0.17% |
| SSE Composite Index | 4,097.94 | 22.84 | 0.56% |